Neutre
No significant market-moving news for Eli Lilly (LLY) in the past 24 hours.
Ce briefing n’est pas encore disponible dans cette langue — version anglaise affichée.
Over the past 24 hours, there have been no significant developments affecting Eli Lilly's stock performance. The company continues to benefit from strong demand for its weight-loss and diabetes medications, Mounjaro and Zepbound, which have been key drivers of its recent growth. Additionally, Eli Lilly's dividend growth streak remains intact, with a 15.3% increase announced in December 2025.
Points clés
- No new market-moving news in the past 24 hours.
- Sustained high demand for Mounjaro and Zepbound continues to drive revenue growth.
- Eli Lilly's 12-year dividend growth streak, with a 15.3% increase in December 2025, reflects financial strength.
Sources
Généré par IA à partir de sources d'actualités publiques. Ceci n'est pas un conseil financier.
